GlassScriptPhysician profile
Rachel Fetner
NPI 1437184850
$9,361.13
in general payments reported to CMS, 2019-2025
45 companies · $751 in 2025
The $751 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,015 · 2020: $960 · 2021: $1,446 · 2022: $1,890 · 2023: $1,780 · 2024: $1,519 · 2025: $751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,050.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,050.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $866.19 | 2019-2025 | Evenity, Prolia, Tepezza |
| Lilly USA, LLC | $803.61 | 2019-2025 | Jardiance, Mounjaro, Lyumjev |
| Sanofi-Aventis U.S. LLC | $664.54 | 2019-2024 | |
| Xeris Pharmaceuticals, INC. | $664.40 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Abbott Laboratories | $615.66 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $589.00 | 2019-2024 | Cycloset |
| Novo Nordisk INC | $574.41 | 2019-2025 | Ozempic |
| Astrazeneca Pharmaceuticals LP | $530.44 | 2019-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $475.25 | 2019-2024 | Synjardy, Jardiance, Tradjenta |
| Amneal Pharmaceuticals LLC | $444.48 | 2019-2025 | Unithroid |
| Abbvie INC. | $422.99 | 2019-2025 | |
| Radius Health, INC. | $384.19 | 2020-2025 | Tymlos |
| Dexcom, INC. | $322.43 | 2021-2024 | Dexcom G6 Transmitter |
| Lifescan, INC. | $226.74 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $207.42 | 2019-2021 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Fetner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.